What are the recommended diagnostic steps and treatment options for non‑alcoholic fatty liver disease (NAFLD)?

Diagnosing and Treating Non-Alcoholic Fatty Liver Disease (NAFLD)

Diagnostic Approach

Use a two-stage risk stratification strategy starting with FIB-4 score to identify patients with clinically significant fibrosis, reserving liver biopsy only for cases with diagnostic uncertainty or when evaluating patients for specific drug therapies. 1, 2

Step 1: Identify At-Risk Patients

Screen the following high-risk populations without requiring initial imaging 2:

• Patients with type 2 diabetes mellitus 2
• Patients with obesity (BMI ≥30 kg/m²) 2, 3
• Patients with metabolic syndrome 3, 4
• Incidental hepatic steatosis found on imaging with elevated liver enzymes 2

Step 2: Initial Laboratory Evaluation

Obtain these specific tests 2:

• Comprehensive metabolic panel (includes ALT, AST, albumin) 2
• Complete blood count (for platelet count) 2
• Alcohol screening using AUDIT or AUDIT-C questionnaire 2
• Exclude other liver diseases: hepatitis B surface antigen, hepatitis C antibody, iron studies, autoimmune markers 1

Step 3: Non-Invasive Fibrosis Assessment

Calculate FIB-4 score as the first-tier test (age × AST / [platelet count × √ALT]) 2:

• FIB-4 <1.3 (or <2.0 if age >65 years): Advanced fibrosis excluded; repeat testing in 2-3 years 2
• FIB-4 1.3-2.67: Indeterminate zone; proceed to second-tier testing 2
• FIB-4 >2.67: High risk for advanced fibrosis; proceed to second-tier testing 2

Step 4: Second-Tier Testing for Indeterminate or High-Risk Scores

Use one of the following 1:

• Transient elastography (FibroScan) 1
• Enhanced Liver Fibrosis (ELF) test 1
• Acoustic Radiation Force Impulse (ARFI) imaging 1

This two-stage approach reduces indeterminate results and reserves liver biopsy for a minority of patients 1.

Step 5: Liver Biopsy Indications

Perform liver biopsy only in these specific situations 1:

• Diagnostic uncertainty when other liver diseases cannot be excluded non-invasively 1
• Evaluating for NASH severity when considering enrollment in clinical trials or experimental drug therapies 1
• Discordant non-invasive fibrosis markers where determining cirrhosis status (F4) is critical for hepatocellular carcinoma surveillance 1

The biopsy should be reported using NASH Clinical Research Network (NAS) or Steatosis-Activity-Fibrosis (SAF) scoring systems 1.

Treatment Approach

Primary Treatment: Weight Loss Through Lifestyle Modification

Achieve 7-10% weight loss through combined dietary restriction and exercise, as this is the only intervention proven to improve liver histology. 3, 5, 4

Dietary Interventions

• Mediterranean diet with 500-1000 kcal/day deficit 5
• Low-calorie ketogenic diet as an alternative 6
• High-protein diet for patients who prefer this approach 6
• Target weight loss of at least 7-10% of body weight 3, 4

Exercise Prescription

• 200 minutes per week of moderate-intensity aerobic exercise 5
• This equates to approximately 30-40 minutes daily 5
• Exercise provides benefit even without significant weight loss 7

Pharmacological Treatment

Reserve pharmacological therapy for patients with biopsy-proven NASH and significant fibrosis (≥F2) who have not responded to lifestyle interventions. 1, 3

For Patients with Type 2 Diabetes and NASH

• GLP-1 receptor agonists (e.g., dulaglutide, semaglutide): First-line pharmacotherapy due to weight loss and metabolic benefits 3, 6
• Pioglitazone 30-45 mg daily: Improves liver histology in patients with biopsy-proven NASH 3
• SGLT-2 inhibitors: Consider as adjunctive therapy, particularly tofogliflozin combined with pioglitazone 7, 6

For Patients without Diabetes

• Vitamin E 800 IU daily: Consider in non-diabetic patients with biopsy-proven NASH without cirrhosis 3, 4
• GLP-1 receptor agonists: Emerging evidence supports use even in non-diabetic patients 3

Important caveat: No FDA-approved medications specifically for NAFLD/NASH currently exist; these are off-label uses 3, 4.

Bariatric Surgery

Consider bariatric surgery for patients with BMI ≥35 kg/m² (or ≥30 kg/m² with comorbidities) who have failed lifestyle interventions. 3, 5

• Bariatric surgery improves steatosis, inflammation, and fibrosis in most patients 3
• Metabolic endoscopy represents an alternative for selected patients 5

Surveillance for Complications

For Patients with NAFLD Cirrhosis

Implement these surveillance protocols 1:

• Hepatocellular carcinoma screening: Ultrasound with or without AFP every 6 months 1
• Variceal screening: Upper endoscopy unless Baveno VI exclusion criteria met (liver stiffness <20 kPa AND platelets >150 × 10⁹/L) 1
• Expanded Baveno VI criteria (liver stiffness <25 kPa AND platelets >110 × 10⁹/L) can also safely exclude need for endoscopy 1

Ongoing Monitoring

• Repeat FIB-4 or elastography every 1-3 years in patients without advanced fibrosis to detect progression 1, 2
• Monitor cardiovascular risk factors aggressively, as cardiovascular disease is the leading cause of death in NAFLD patients 3, 4, 7

Critical Pitfalls to Avoid

• Do not screen the general population for NAFLD, even though prevalence is 25-30%; focus only on high-risk groups 4
• Do not perform liver biopsy routinely; the two-stage non-invasive approach identifies most patients needing intervention 1, 2
• Do not use FIB-4 cutoffs designed for younger patients in those >65 years; use the higher threshold of 2.0 instead of 1.3 2
• Do not ignore extrahepatic complications: chronic kidney disease, extrahepatic malignancies, and cardiovascular disease significantly impact outcomes 7
• Do not assume normal ALT excludes significant disease, though elevated ALT increases risk of progression to cirrhosis 2